4 active not recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 4 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Immunoblastic Lymphadenopathy: new trials by email Literature Review of Immunoblastic Lymphadenopathy trials Research Report on Immunoblastic Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-25 | 2026-10-29 |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Brentuximab Vedotin, Cyclophosphamide, Doxorubicin - Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative | Phase 2 | Active not recruiting | City of Hope Medical Center | 48 | 2017-12-04 | 2026-11-06 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders busulfan, cyclophosphamide, cyclosporine - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Active not recruiting | City of Hope Medical Center | 260 | 2001-10-16 | 2026-06-02 |
Lymphoma, Large-Cell, Anaplastic (4) · Lymphoma, T-Cell (3) · Mycosis Fungoides (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Enteropathy-Associated T-Cell Lymphoma (2) · Lymphoma (2) · Lymphoma, Extranodal NK-T-Cell (2) · Lymphoma, Follicular (2) · Recurrence (2) · Anemia, Aplastic (1) · Anemia, Refractory, with Excess of Blasts (1) · Blast Crisis (1) · Burkitt Lymphoma (1) · Congenital Abnormalities (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphadenopathy (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Hematologic Diseases (3) · Leukemia, Lymphoid (3) · Lymphoma, Non-Hodgkin (3) · Disease Attributes (2) · Leukemia (2) · Lymphoma (2) · Lymphoma, T-Cell, Cutaneous (2)
Cyclophosphamide (2) · Etoposide (2) · 10-propargyl-10-deazaaminopterin (1) · Brentuximab Vedotin (1) · Busulfan (1) · Cyclosporine (1) · Doxorubicin (1) · Melphalan (1) · Methotrexate (1) · Mycophenolic Acid (1) · Peripheral Blood Stem Cell Transplantation (1) · Prednisone (1) · Sirolimus (1) · Tacrolimus (1) · Whole-Body Irradiation (1)
City of Hope Medical Center (3) · Bristol-Myers Squibb (1)
United States (2) · Canada (1) · Japan (1)
Alex F Herrera (2) · Auayporn P. Nademanee, MD (1)
P30CA033572 (2)